Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

https://www.accesswire.com/709117/Manhattan-BioSolutions-Inc-Signs-Commercial-Evaluation-License-Agreements-with-the-National-Institutes-of-Health-NIH-for-Use-of-Monoclonal-Antibodies-in-Novel-Antibody-Drug-Conjugate-ADC-Oncology-Programs NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation […]

Published January 3, 2024

Manhattan BioSolutions Enters into Evaluation and Potential Licensing Agreement with Biocytogen for Use of Innovative Antibodies in Targeted Therapies

Published April 9, 2024

Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024

Published July 1, 2018

Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan

https://jlabs.jnjinnovation.com/quickfire-challenges/jlabs-nyc-quickfire-challenge#paragraph-5131 https://www.prnewswire.com/news-releases/johnson–johnson-innovation-opens-jlabs–nyc-in-collaboration-with-new-york-state-and-the-new-york-genome-center-300670313.html